跳至主要内容
临床试验/CTRI/2022/01/039286
CTRI/2022/01/039286已完成不适用

An Open Label Prospective Randomized Controlled Study to Assess the Efficacy of the Homoeopathic Formulation ‘Ruck– Pain’ in the Treatment of Spondylosis

Dr Willmar Schwabe India Pvt Ltd1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年1月2日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
1
主要终点
Improvement in the Mobility of the Patient

研究概览

简要总结

Spondylosis is a type of arthritis spurred by wear and tear to the spine. It happens when discs and joints degenerate, when bone spurs grow on the vertebrae, or both. These changes can impair the spine’s movement and affect the nerves and other functions. Ruck-Pain Homoeopathic Formulation Medicine Produced and Marketed by Dr Willmar Schwabe India Pvt Ltd acts on Spinal Disorders. This Proposed Clinical Trial aims at its Clincial Verification.

研究设计

研究类型
Interventional
分配方式
Other
盲法
Open Label

入排标准

年龄范围
45.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Clinically and / or Radiologically Diagnosed Spondylosis Patients.

排除标准

  • Congenital Spinal anomalies; fracture spine; advanced degenerative spinal conditions; severe neural cord compression; severe bony ankylosis; patients with advanced neurological symptoms; cervical rib.

结局指标

主要结局

Improvement in the Mobility of the Patient

时间窗: 90 Days

Symptomatic Relief of the pain

时间窗: 90 Days

次要结局

  • Improvement in Quality of life of the patient, Improvement in patient mobilization, etc.,(90 Days)

研究者

申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验